Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin-like Transcript 2 (ILT2)
- Target
- ILT2
- Molecular classification
- Leukocyte immunoglobulin-like receptor (LILR), Receptor
01
Overview
Immunoglobulin-like transcript 2 (ILT2) is an inhibitory immune receptor expressed on a variety of immune cells, including subsets of T cells, natural killer (NK) cells, B cells, and monocytes. It plays a significant role in regulating immune responses by dampening the activation and cytotoxic functions of these cells. The primary ligands are classical and non-classical MHC class I molecules, with highest affinity for HLA-G. ILT2 engagement leads to recruitment of phosphatases such as SHP-1 via ITIM motifs, resulting in negative signaling.
- Other names
- LIR-1LILRB1CD85j
02
Mechanism of action
Antibody-mediated blockade restores cytolytic capacity of exhausted/inhibited NK or T cells. Lenalidomide modulates ligand expression.
03
Biological functions
Immune regulationInhibition of NK cell cytotoxicitySuppression of T cell responsesRegulation of peripheral tolerance
04
Disease associations
CancerChronic lymphocytic leukemia (CLL)Immune evasionTumor microenvironment
05
Safety considerations
Potential for off-target effects due to broad expression on immune cellsRisk of autoimmunity if immune checkpoint inhibition is excessive
06
Interacting drugs
Antibody-mediated blockade of ILT2
1 more in the full profile.
07
Biomarkers
ILT2 expression levels (potential biomarker for response to immunotherapies, e.g., oncolytic virus treatments)
Beyond the preview
Go deeper on Immunoglobulin-like Transcript 2 (ILT2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin-like Transcript 2 (ILT2).